Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56 bright natural ki...
Main Authors: | Jana Lizrova Preiningerova, Marta Vachova |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285616671887 |
Similar Items
-
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
by: Monica A. Rojas, et al.
Published: (2009-09-01) -
Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
by: Reardon J, et al.
Published: (2013-10-01) -
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
by: Tran JQ, et al.
Published: (2016-02-01) -
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
by: Cohan S
Published: (2016-09-01) -
Immunomodulatory treatments for relapsing–remitting multiple sclerosis
by: Fritz Leutmezer
Published: (2017-01-01)